Differences in lipid metabolism in acquired versus preexisting glucose intolerance during gestation: role of free fatty acids and sphingosine-1-phosphate.


Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
08 Oct 2022
Historique:
received: 30 06 2022
accepted: 23 09 2022
entrez: 8 10 2022
pubmed: 9 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide. There is increasing evidence that GDM is a heterogeneous disease with different subtypes. An important question in this context is whether impaired glucose tolerance (IGT), which is a typical feature of the disease, may already be present before pregnancy and manifestation of the disease. The latter type resembles in its clinical manifestation prediabetes that has not yet manifested as type 2 diabetes (T2DM). Altered lipid metabolism plays a crucial role in the disorder's pathophysiology. The aim was to investigate the role of lipids which are relevant in diabetes-like phenotypes in these both models with different time of initial onset of IGT. Two rodent models reflecting different characteristics of human GDM were used to characterize changes in lipid metabolism occurring during gestation. Since the New Zealand obese (NZO)-mice already exhibit IGT before and during gestation, they served as a subtype model for GDM with preexisting IGT (preIGT) and were compared with C57BL/6 N mice with transient IGT acquired during gestation (aqIGT). While the latter model does not develop manifest diabetes even under metabolic stress conditions, the NZO mouse is prone to severe disease progression later in life. Metabolically healthy Naval Medical Research Institute (NMRI) mice served as controls. In contrast to the aqIGT model, preIGT mice showed hyperlipidemia during gestation with elevated free fatty acids (FFA), triglycerides (TG), and increased atherogenic index. Interestingly, sphingomyelin (SM) concentrations in the liver decreased during gestation concomitantly with an increase in the sphingosine-1-phosphate (S1P) concentration in plasma. Further, preIGT mice showed impaired hepatic weight adjustment and alterations in hepatic FFA metabolism during gestation. This was accompanied by decreased expression of peroxisome proliferator-activated receptor alpha (PPARα) and lack of translocation of fatty acid translocase (FAT/CD36) to the hepatocellular plasma membrane. The preIGT model showed impaired lipid metabolism both in plasma and liver, as well as features of insulin resistance consistent with increased S1P concentrations, and in these characteristics, the preIGT model differs from the common GDM subtype with aqIGT. Thus, concomitantly elevated plasma FFA and S1P concentrations, in addition to general shifts in sphingolipid fractions, could be an interesting signal that the metabolic disorder existed before gestation and that future pregnancies require more intensive monitoring to avoid complications. This graphical abstract was created with BioRender.com .

Sections du résumé

BACKGROUND BACKGROUND
The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide. There is increasing evidence that GDM is a heterogeneous disease with different subtypes. An important question in this context is whether impaired glucose tolerance (IGT), which is a typical feature of the disease, may already be present before pregnancy and manifestation of the disease. The latter type resembles in its clinical manifestation prediabetes that has not yet manifested as type 2 diabetes (T2DM). Altered lipid metabolism plays a crucial role in the disorder's pathophysiology. The aim was to investigate the role of lipids which are relevant in diabetes-like phenotypes in these both models with different time of initial onset of IGT.
METHODS METHODS
Two rodent models reflecting different characteristics of human GDM were used to characterize changes in lipid metabolism occurring during gestation. Since the New Zealand obese (NZO)-mice already exhibit IGT before and during gestation, they served as a subtype model for GDM with preexisting IGT (preIGT) and were compared with C57BL/6 N mice with transient IGT acquired during gestation (aqIGT). While the latter model does not develop manifest diabetes even under metabolic stress conditions, the NZO mouse is prone to severe disease progression later in life. Metabolically healthy Naval Medical Research Institute (NMRI) mice served as controls.
RESULTS RESULTS
In contrast to the aqIGT model, preIGT mice showed hyperlipidemia during gestation with elevated free fatty acids (FFA), triglycerides (TG), and increased atherogenic index. Interestingly, sphingomyelin (SM) concentrations in the liver decreased during gestation concomitantly with an increase in the sphingosine-1-phosphate (S1P) concentration in plasma. Further, preIGT mice showed impaired hepatic weight adjustment and alterations in hepatic FFA metabolism during gestation. This was accompanied by decreased expression of peroxisome proliferator-activated receptor alpha (PPARα) and lack of translocation of fatty acid translocase (FAT/CD36) to the hepatocellular plasma membrane.
CONCLUSION CONCLUSIONS
The preIGT model showed impaired lipid metabolism both in plasma and liver, as well as features of insulin resistance consistent with increased S1P concentrations, and in these characteristics, the preIGT model differs from the common GDM subtype with aqIGT. Thus, concomitantly elevated plasma FFA and S1P concentrations, in addition to general shifts in sphingolipid fractions, could be an interesting signal that the metabolic disorder existed before gestation and that future pregnancies require more intensive monitoring to avoid complications. This graphical abstract was created with BioRender.com .

Identifiants

pubmed: 36209101
doi: 10.1186/s12944-022-01706-x
pii: 10.1186/s12944-022-01706-x
pmc: PMC9547403
doi:

Substances chimiques

Fatty Acids, Nonesterified 0
Lysophospholipids 0
PPAR alpha 0
Sphingolipids 0
Sphingomyelins 0
Triglycerides 0
sphingosine 1-phosphate 26993-30-6
Sphingosine NGZ37HRE42

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99

Informations de copyright

© 2022. The Author(s).

Références

Lipids. 1975 Oct;10(10):643-5
pubmed: 1186452
Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1219-1231
pubmed: 30651660
Mediators Inflamm. 2015;2015:520618
pubmed: 26648664
CSH Protoc. 2008 May 01;2008:pdb.prot4989
pubmed: 21356832
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3822-3829
pubmed: 28938429
Physiol Rep. 2020 May;8(9):e14417
pubmed: 32374082
Genome Res. 1996 Oct;6(10):995-1001
pubmed: 8908519
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Am J Pathol. 1975 Dec;81(3):545-60
pubmed: 1239955
EMBO J. 2021 Jul 1;40(13):e106272
pubmed: 33942347
PLoS One. 2015 Dec 03;10(12):e0144027
pubmed: 26633694
PLoS One. 2015 Jan 30;10(1):e0116858
pubmed: 25635851
Liver Int. 2010 Mar;30(3):406-15
pubmed: 20040050
Metabolism. 2010 Jul;59(7):943-50
pubmed: 20022072
Front Endocrinol (Lausanne). 2019 Aug 21;10:577
pubmed: 31496996
Methods Mol Biol. 2012;933:59-73
pubmed: 22893401
Cells. 2020 Jul 13;9(7):
pubmed: 32668665
Diabetologia. 2000 May;43(5):673-80
pubmed: 10855543
Reproduction. 2017 Aug;154(2):153-165
pubmed: 28559474
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Arch Gynecol Obstet. 2013 Jul;288(1):49-55
pubmed: 23400357
Nat Methods. 2018 Dec;15(12):994-996
pubmed: 30504873
Diabetes Care. 2022 Apr 1;45(4):864-870
pubmed: 35104325
Diabetes Care. 2016 Jun;39(6):1052-5
pubmed: 27208340
Diabetes Care. 2016 Dec;39(12):2232-2239
pubmed: 27703025
Curr Opin Cell Biol. 2017 Aug;47:117-125
pubmed: 28641181
PLoS Genet. 2012;8(10):e1003010
pubmed: 23071457
J Lipid Res. 2011 Mar;52(3):509-17
pubmed: 21068007
Mamm Genome. 2014 Oct;25(9-10):401-12
pubmed: 24752583
J Chromatogr. 1987 Jan 30;387:323-31
pubmed: 3558628
Gut. 2011 Oct;60(10):1394-402
pubmed: 21270117
Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1323-32
pubmed: 18812462
Diabetes Care. 2003 Mar;26(3):819-24
pubmed: 12610043
EClinicalMedicine. 2021 Aug 12;40:101087
pubmed: 34746711
Diabetes Res Clin Pract. 2022 Jan;183:109050
pubmed: 34883186
J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2825-e2832
pubmed: 35359001
Obesity (Silver Spring). 2012 Jul;20(7):1403-12
pubmed: 22331130
Mol Endocrinol. 1995 Jul;9(7):794-804
pubmed: 7476963
J Nutr. 1990 Apr;120(4):338-45
pubmed: 2329388
Aust J Exp Biol Med Sci. 1956 Jun;34(3):181-98
pubmed: 13363746
Pharmacol Res. 2009 Sep;60(3):151-9
pubmed: 19646654
Anat Rec (Hoboken). 2013 Mar;296(3):378-81
pubmed: 23382140
Physiol Res. 2008;57(5):727-734
pubmed: 17949248
Obstet Gynecol. 1993 Apr;81(4):523-8
pubmed: 8459960
J Mol Endocrinol. 1999 Feb;22(1):1-8
pubmed: 9924174
Am J Obstet Gynecol. 1988 Nov;159(5):1043-7
pubmed: 3189435
FASEB J. 2015 Sep;29(9):3638-53
pubmed: 25985799
Cells. 2020 Aug 11;9(8):
pubmed: 32796572
Mol Syst Biol. 2012;8:615
pubmed: 23010998
Am J Physiol Endocrinol Metab. 2012 Aug 15;303(4):E504-14
pubmed: 22693206
J Lipid Res. 2000 Sep;41(9):1524-31
pubmed: 10974060
Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E522-33
pubmed: 11832353
BMC Pregnancy Childbirth. 2013 Jan 16;13:9
pubmed: 23324111
Gynecol Obstet Invest. 1988;25(3):158-64
pubmed: 3391425
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
J Pediatr. 2015 Feb;166(2):276-81.e6
pubmed: 25454937
Proc Natl Acad Sci U S A. 2021 Nov 30;118(48):
pubmed: 34815335
Am J Physiol Endocrinol Metab. 2017 Oct 1;313(4):E463-E472
pubmed: 28420650
Horm Metab Res. 2013 Jun;45(6):430-5
pubmed: 23322514
Am J Transl Res. 2016 Aug 15;8(8):3574-84
pubmed: 27648148
Gastroenterology. 2008 Feb;134(2):556-67
pubmed: 18242221
BMC Bioinformatics. 2012 Jun 18;13:134
pubmed: 22708584
Int J Mol Sci. 2022 Jun 15;23(12):
pubmed: 35743136
Endocrinology. 2016 Feb;157(2):570-85
pubmed: 26650570
Diabetologia. 2019 Aug;62(8):1445-1452
pubmed: 31177313
Lipids Health Dis. 2021 Sep 29;20(1):125
pubmed: 34587947
Obesity (Silver Spring). 2010 Aug;18(8):1608-13
pubmed: 20019684
J Alzheimers Dis. 2010;21(3):967-84
pubmed: 20693650
J Biochem. 1987 Jul;102(1):83-92
pubmed: 3667567
J Hepatol. 2018 Sep;69(3):705-717
pubmed: 29705240
Diabetes Care. 2000 Nov;23(11):1679-85
pubmed: 11092292
Genome Res. 1996 Oct;6(10):986-94
pubmed: 8908518
Best Pract Res Clin Endocrinol Metab. 2010 Aug;24(4):515-25
pubmed: 20832733
FASEB J. 2009 Jan;23(1):271-8
pubmed: 18827021
Diabetologia. 2007 Dec;50(12):2476-85
pubmed: 17922105
PLoS One. 2013 Sep 06;8(9):e72449
pubmed: 24039766
Physiol Rev. 2010 Jan;90(1):367-417
pubmed: 20086080
J Biol Chem. 1998 Mar 6;273(10):5678-84
pubmed: 9488698
Diabetes Care. 1988 May;11(5):402-11
pubmed: 3391090
Glycoconj J. 2016 Dec;33(6):927-936
pubmed: 27318478
J Clin Med. 2020 Apr 16;9(4):
pubmed: 32316284
Elife. 2020 Aug 04;9:
pubmed: 32748787
Nutr Metab (Lond). 2021 Apr 13;18(1):40
pubmed: 33849585
Int J Mol Sci. 2022 Jun 09;23(12):
pubmed: 35742878
Diabetes. 1973 Apr;22(4):251-5
pubmed: 4572201
Am J Physiol Endocrinol Metab. 2015 Dec 15;309(12):E968-80
pubmed: 26487005
Lipids Health Dis. 2009 Apr 06;8:13
pubmed: 19344534
Am J Physiol Endocrinol Metab. 2013 Dec 1;305(11):E1327-38
pubmed: 24085033
Mol Pharmacol. 1998 Jan;53(1):14-22
pubmed: 9443928
PLoS One. 2013 Sep 27;8(9):e74341
pubmed: 24086336
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:7-12
pubmed: 29328940
Diabetes Metab. 2000 Nov;26(5):393-401
pubmed: 11119019
Diabetes. 1992 Dec;41(12):1651-9
pubmed: 1446807
BMC Med. 2019 Jan 21;17(1):15
pubmed: 30661507
Endocrinology. 2010 Jan;151(1):96-102
pubmed: 19906813
Clin Nutr. 2021 Jun;40(6):4140-4148
pubmed: 33610418
Int J Obes (Lond). 2014 Oct;38(10):1282-9
pubmed: 24785102
Nucleic Acids Res. 2010 Jan;38(Database issue):D792-9
pubmed: 19906719
Diabetologia. 2014 Feb;57(2):373-82
pubmed: 24292566
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E315-22
pubmed: 19470830
Diabetes. 2007 Dec;56(12):2863-71
pubmed: 17728375
Int J Mol Sci. 2021 Aug 31;22(17):
pubmed: 34502370
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339

Auteurs

Moritz Liebmann (M)

Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, D-38106, Braunschweig, Germany.

Katharina Grupe (K)

Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, D-38106, Braunschweig, Germany.

Melissa Asuaje Pfeifer (M)

Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, D-38106, Braunschweig, Germany.

Ingo Rustenbeck (I)

Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, D-38106, Braunschweig, Germany.

Stephan Scherneck (S)

Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, D-38106, Braunschweig, Germany. s.scherneck@tu-braunschweig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH